Hematopoietic stem cell transplantation for curing children with severe autoimmune diseases: Is this a valid option?

Paediatric Oncology and Haematology Unit Lalla Seràgnoli, Department of Paediatrics, University of Bologna Sant'Orsola-Malpighi Hospital, Bologna, Italy.
Pediatric Transplantation (Impact Factor: 1.44). 04/2012; 16(5):413-25. DOI: 10.1111/j.1399-3046.2012.01691.x
Source: PubMed


The cure of children with severe AD, especially patients with severe, progressive, and therapy-resistant autoimmunity, represents a challenge for current medical practice. The idea of HSCT as a promising therapeutic opportunity was borne accidentally from finding patients who, after undergoing HSCT for a hematological indication, were cured of a concomitant AD. Thus, over the last two decades, HSCT has been extensively investigated, and it has become an appealing therapy for rheumatological (juvenile rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis) and hematological diseases (immune cytopenias). Recently, interesting results have been also described in type 1 diabetes mellitus and Crohn's disease. Although the use of HSCT has been steadily rising in the last few years, many questions are still open, especially after the discoveries of many new biological agents. Given the low incidence of ADs in children, most of the data about the use of the HSCT for these diseases are taken from a mixed cohort of adults and children. The aim of this review is to summarize the published studies and to try to answer the question as to whether this procedure can be considered a promising approach.

13 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The immunoregulatory properties of hematopoietic stem cells (HSCs) have been recognized for more than 60 years, beginning in 1945, when Owen reported that genetically disparate freemartin cattle sharing a common placenta were red blood cell chimeras. In 1953, Billingham, Brent, and Medawar demonstrated that murine neonatal chimeras prepared by infusion of donor-derived hematopoietic cells exhibited donor-specific tolerance to skin allografts. Various approaches using HSCs in organ transplantation have gradually brought closer to reality the dream of inducing donor-specific tolerance in organ transplant recipients. Several hurdles needed to be overcome, especially the risk of graft-versus-host disease (GVHD), the toxicity of ablative conditioning, and the need for close donor-recipient matching. For wide acceptance, HSC therapy must be safe and reproducible in mismatched donor-recipient combinations. Discoveries in other disciplines have often unexpectedly and synergistically contributed to progress in this area. This review presents a historic perspective of the quest for tolerance in organ transplantation, highlighting current clinical approaches.Clinical Pharmacology & Therapeutics (2012); advance online publication 5 December 2012. doi:10.1038/clpt.2012.201.
    Clinical Pharmacology &#38 Therapeutics 10/2012; 93(1). DOI:10.1038/clpt.2012.201 · 7.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We analysed the long term outcomes of paediatric patients registered in the European Group for Blood and Marrow Transplantation (EBMT) database who received hematopoietic stem cell transplantation (HSCT) for severe treatment refractory autoimmune cytopenia. With a median follow-up of 100 months, event free survival was 54% overall, with no significant difference between allogeneic (n=15) andautologous (n=7) HSCT (58% versus 42%, p= 0.5). Despite a trend to failure of response or relapse following autologous compared with allogeneic HSCT, the difference was not significant (43% versus 13%, p=0.3). Treatment related mortality was high in both HSCT groups (29% versus 16%; p= 0.09). Based on the limited numbers in this retrospective analysis, both allogeneic and autologous HSCT may induce complete and persistent responses in around half of pediatric patients with severe refractory autoimmune cytopenia, although treatment related toxicity is high.
    Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 12/2012; 19(4). DOI:10.1016/j.bbmt.2012.12.008 · 3.40 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The diagnosis and management of children with autoimmune cytopenias can be challenging. Children can present with immune-mediated destruction of a single-cell lineage or multiple cell lineages, including platelets (immune thrombocytopenia [ITP]), erythrocytes (autoimmune hemolytic anemia), and neutrophils (autoimmune neutropenia). Immune-mediated destruction can be primary or secondary to a comorbid immunodeficiency, malignancy, rheumatologic condition, or lymphoproliferative disorder. Treatment options generally consist of nonspecific immune suppression or modulation. This nonspecific approach is changing as recent insights into disease biology have led to targeted therapies, including the use of thrombopoietin mimetics in ITP and sirolimus for cytopenias associated with autoimmune lymphoproliferative syndrome.
    Pediatric Clinics of North America 12/2013; 60(6):1489-511. DOI:10.1016/j.pcl.2013.08.009 · 2.12 Impact Factor
Show more